L020 Stock Overview
Engages in the provision of product testing, safety assessment, and compliance services primarily to the cosmetics, consumer packaged and household goods, and nutraceutical industries in the United Kingdom and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Britannia Life Sciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.019 |
| 52 Week High | CA$0.066 |
| 52 Week Low | CA$0.005 |
| Beta | 0.46 |
| 11 Month Change | -11.36% |
| 3 Month Change | n/a |
| 1 Year Change | -23.53% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.56% |
Recent News & Updates
Recent updates
Shareholder Returns
| L020 | DE Professional Services | DE Market | |
|---|---|---|---|
| 7D | 254.5% | 3.3% | 0.8% |
| 1Y | -23.5% | -50.4% | 9.1% |
Return vs Industry: L020 exceeded the German Professional Services industry which returned -51.3% over the past year.
Return vs Market: L020 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| L020 volatility | |
|---|---|
| L020 Average Weekly Movement | 117.1% |
| Professional Services Industry Average Movement | 4.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: L020's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: L020's weekly volatility has increased from 70% to 117% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Pete Shippen | britannia.life |
Britannia Life Sciences Inc. engages in the provision of product testing, safety assessment, and compliance services primarily to the cosmetics, consumer packaged and household goods, and nutraceutical industries in the United Kingdom and internationally. The company is headquartered in Toronto, Canada.
Britannia Life Sciences Inc. Fundamentals Summary
| L020 fundamental statistics | |
|---|---|
| Market cap | €5.53m |
| Earnings (TTM) | -€3.67m |
| Revenue (TTM) | €5.03m |
1.5x
P/S Ratio-2.1x
P/E RatioIs L020 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| L020 income statement (TTM) | |
|---|---|
| Revenue | CA$7.38m |
| Cost of Revenue | CA$2.81m |
| Gross Profit | CA$4.57m |
| Other Expenses | CA$9.96m |
| Earnings | -CA$5.39m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.033 |
| Gross Margin | 61.95% |
| Net Profit Margin | -72.99% |
| Debt/Equity Ratio | 104.4% |
How did L020 perform over the long term?
See historical performance and comparison